Replies to post #173029 on Biotech Values

[mouton29]

Prana - they have filed a 6-K with the SEC, with a presentation. I only skimmed it, but noticed that they are saying the Alzheimer's trial is expected to report in March, a bit more specific than the December 30 press release, which said first quarter.

The updated corporate presentation includes:
· Information on the Company’s development programs and major catalysts;
· Status of the Huntington’s Disease phase 2 clinical trial which is nearing the reporting of major clinical results and market environment;
· Status of the Alzheimer’s Disease phase 2 clinical trial, which is expected to report in March 2014 and market environment; and
· The novel approach of PBT in potentially inhibiting Alzheimer's-like changes in the brain by preventing a build up of beta-amyloid aggregates, which destroy cognitive function, as well providing a neuroprotective and neurotrophic effect.

http://www.sec.gov/Archives/edgar/data/1131343/000114420414003209/v3659396k.htm